Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole
- PMID: 20137065
- PMCID: PMC2829550
- DOI: 10.1186/1471-2210-10-2
Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole
Abstract
Background: Pramipexole exists as two isomers. The S(-) enantiomer is a potent D3/D2 receptor agonist and is extensively used in the management of PD. In contrast, the R(+) enantiomer is virtually devoid of any of the DA agonist effects. Very limited studies are available to characterize the pharmacological spectrum of the R(+) enantiomer of pramipexole.
Results: Using differentiated SH-SY5Y neuroblastoma cells as an experimental model, here we show that S(-) and R(+) pramipexole are endowed with equipotent efficacy in preventing cell death induced by H2O2 and inhibiting mitochondrial reactive oxygen species generation. Both pramipexole enantiomers prevented mitochondrial ROS generation with a potency about ten times higher then that elicited for neuroprotection.
Conclusions: These results support the concept of both S(-) and R(+) pramipexole enantiomers as mitochondria-targeted antioxidants and suggest that the antioxidant, neuroprotective activity of these drugs is independent of both the chiral 6-propylamino group in the pramipexole molecule and the DA receptor stimulation.
Figures




References
-
- Schapira AH. Neuroprotection in PD - a role for dopamine agonists? Neurology. 2003;61:S34–S42. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources